Outlook Therapeutics, Inc. (NASDAQ:OTLK - Get Free Report) Director Yezan Munther Haddadin acquired 1,882 shares of the company's stock in a transaction on Thursday, March 28th. The stock was acquired at an average price of $11.82 per share, with a total value of $22,245.24. Following the purchase, the director now directly owns 5,049 shares in the company, valued at $59,679.18. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.
Outlook Therapeutics Stock Performance
Shares of NASDAQ:OTLK opened at $11.94 on Friday. The firm has a 50 day moving average of $8.31 and a 200-day moving average of $7.92. Outlook Therapeutics, Inc. has a 12 month low of $4.00 and a 12 month high of $40.60.
Outlook Therapeutics (NASDAQ:OTLK - Get Free Report) last issued its earnings results on Wednesday, February 14th. The company reported ($0.80) EPS for the quarter, beating the consensus estimate of ($1.00) by $0.20. As a group, equities research analysts predict that Outlook Therapeutics, Inc. will post -2.99 earnings per share for the current fiscal year.
Analyst Ratings Changes
Have You Seen Elon’s New A.I. Device? (Picture Inside)
From InvestorPlace | Ad
A strange new era for mankind is upon us...
And it's all thanks to Elon Musk's latest creation. Click here to see this strange device you could be wearing some day.
Elon believes A.I. is advancing so fast...
This strange new device to protect us against that A.I. threat...
OTLK has been the subject of several analyst reports. Guggenheim upgraded shares of Outlook Therapeutics from a "neutral" rating to a "buy" rating and set a $40.00 price objective for the company in a research note on Thursday, January 25th. Ascendiant Capital Markets lifted their price objective on shares of Outlook Therapeutics from $30.00 to $40.00 and gave the stock a "buy" rating in a research note on Friday, December 29th. Brookline Capital Management upgraded shares of Outlook Therapeutics from a "hold" rating to a "buy" rating and set a $31.40 price objective for the company in a research note on Thursday, January 25th. Capital One Financial restated an "overweight" rating on shares of Outlook Therapeutics in a research report on Friday, February 16th. Finally, HC Wainwright boosted their target price on shares of Outlook Therapeutics to $30.00 and gave the company a "buy" rating in a research report on Monday, March 25th. One investment analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $46.43.
Check Out Our Latest Research Report on OTLK
Institutional Inflows and Outflows
Several institutional investors have recently bought and sold shares of the business. Captrust Financial Advisors boosted its position in Outlook Therapeutics by 94.6% during the second quarter. Captrust Financial Advisors now owns 20,568 shares of the company's stock worth $36,000 after purchasing an additional 10,000 shares during the period. Tower Research Capital LLC TRC boosted its position in Outlook Therapeutics by 209.1% during the first quarter. Tower Research Capital LLC TRC now owns 23,546 shares of the company's stock worth $26,000 after purchasing an additional 15,928 shares during the period. BNP Paribas Arbitrage SA boosted its position in Outlook Therapeutics by 174.2% during the second quarter. BNP Paribas Arbitrage SA now owns 25,837 shares of the company's stock worth $26,000 after purchasing an additional 16,414 shares during the period. Commonwealth Equity Services LLC boosted its position in Outlook Therapeutics by 60.5% during the first quarter. Commonwealth Equity Services LLC now owns 26,522 shares of the company's stock worth $28,000 after purchasing an additional 10,000 shares during the period. Finally, CI Private Wealth LLC bought a new position in Outlook Therapeutics during the fourth quarter worth about $31,000. Institutional investors and hedge funds own 11.20% of the company's stock.
About Outlook Therapeutics
(
Get Free Report)
Outlook Therapeutics, Inc, operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
